cancer treatment and research. Professor David Cunningham is the head of the GI and Lymphoma Unit and Director of The Royal Marsden/ICR NIHR Biomedical Research Centre, which he represents at national meetings. He has published over 500 peer- reviewed publications, 45 in the last year alone. Mr Bill Allum is also part of the GI Unit and is the chair of the Oesophago-Gastric Clinical Reference Group, (NHS England Specialist Commissioning), the European Society of Surgical Oncology (European Oesophago Gastric Cancer Audit) and he is also a council member of the International Gastric Cancer Association. And Dr Naureen Starling, a new medical oncologist and researcher published in the field, is helping to develop the GI Unit’s National and International research portfolio and was recently appointed Research Lead for Upper GI Cancers, South London Clinical Research Network.
I am also proud to highlight that The Royal
Marsden is leading the way in skin cancer treatment and trials, a notoriously difficult cancer to treat. Consultant Medical Oncologist James Larkin, who specialises in skin and kidney cancer, is a member of the National Cancer Research Institute (NCRI) Melanoma Clinical Studies Group and Chair of the NCRI Renal Cancer Clinical Studies Group. Prostate cancer research is also an area of growth
for us at The Royal Marsden, and with the addition of equipment such as the da Vinci surgical system, our prostate cancer patients’ prognosis is getting better and better. We are also leading the way in clinical
‘We offer our patients access to world-leading diagnostic techniques, treatments and individualised care plans delivered by internationally
renowned doctors and highly skilled nurses.’ Professor Martin Gore, Medical Director
trials. For example, Professor Johann de Bono has led on the development of multiple important new drugs for prostate cancer, including abiraterone, cabazitaxel, enzalutamide and now PARP inhibitors. He received the prestigious ESMO Award in 2012, has also received an award from the Royal Society of Chemistry for his team’s work in developing the drug abiraterone, and leads the Movember London Prostate Cancer Centre of Excellence. He is also the International Lead for the Stand Up To Cancer Prostate Cancer Dream Team. Dr Chris Parker led the randomised international Phase III trial of Radium 223, also known as alpharadin, in the ALSYMPCA trial for advanced prostate cancer, which has also helped change patient standard of care.
30 Global Opportunity Healthcare 2015 | Issue 01
global-opportunity.co.uk
|
The Royal Marsden
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128